| INTRODUCTION
Epidermal growth factor receptor (EGFR) activating mutations such as exon 19 deletions and L858R point mutations are predictive factors for the effect of EGFR tyrosine kinase inhibitors (EGFR-TKIs) in patients with advanced non-small-cell lung cancer (NSCLC). Epidermal growth factor receptor tyrosine kinase inhibitors prolong progression-free survival (PFS) in patients with NSCLC compared to standard first-line cytotoxic chemotherapy. [1] [2] [3] [4] [5] [6] [7] However, 20%-30% of the patients show primary resistance to EGFR-TKI, although they harbor EGFR activating mutations. 8, 9 Moreover, initial responders to EGFR-TKI treatment acquire resistance and develop recurrence after varying periods. [10] [11] [12] Therefore, the primary and acquired resistance to EGFR-TKI in patients with EGFR activating mutations is a critical problem associated with EGFR-TKI treatment.
EGFR T790M mutation, Met amplification, hepatocyte growth factor (HGF) overexpression, epithelial-mesenchymal transition (EMT), and transformation to small-cell lung cancer [10] [11] [12] have been reported as acquired resistance factors to EGFR-TKI. However, the molecular mechanism of primary resistance is still poorly understood.
Park et al 13 reported that CRIPTO1 expression is associated with primary resistance to EGFR-TKI. Faber et al and Ng et al 14, 15 reported a correlation between BIM deletion and primary resistance to EGFR-TKIs. Yano et al and Engelman et al 16, 17 showed that the HGF-MET pathway induces resistance to gefitinib.
The biochemical characteristics of the tumor microenvironment were delineated as key regulators of resistance to anticancer drugs. [18] [19] [20] [21] The cancer stroma is comprised of various types of immune cells, endothelial cells, fibroblasts, and extracellular matrix (ECM). [22] [23] [24] Within the ECM, collagen type I (Col I) is the most abundantly deposited matrix in the cancer stroma and is produced mainly by fibroblasts. Collagen type I plays an important role in homeostasis in normal tissue as well as cell growth, invasion, and metastasis in cancer tissue. 25, 26 Furthermore, Col I has been reported to impact drug sensitivity.
Collagen type I contributes to gemcitabine resistance in pancreatic cancer through membrane type I-matrix metalloproteinasemediated high mobility group A2 expression. 27 Moreover, integrins such as the Col I receptor in cancer cells promote Src-Akt pathway activation and induce erlotinib resistance in lung cancer cells. 28 However, little has been reported on the influence of Col I on the EGFR-TKI sensitivity of cancer cells.
In the current study, we examined whether Col I can influence the resistance of cancer cells to EGFR-TKI. We also explored the molecular mechanism associated with resistance induced by Col I.
| MATERIALS AND METHODS

| Cell lines and reagents
The EGFR mutant (D E746-A750) human lung adenocarcinoma cell lines PC-9 and HCC 827 were obtained from the ECACC (UK) and The number of mRFP-labeled cancer cells were calculated using the above formula. Each experiment was carried out at least three times.
| Epidermal growth factor receptor-TKI treatment
On day 1 after seeding, the medium was replaced with fresh medium with gefitinib (0.3 lmol/L) (Tocris Bioscience, UK) or dimethyl sulfoxide (DMSO) (Sigma-Aldrich). The cell survival ratio compared Table S1 .
| Tissue sections
To examine the morphophenotypic changes in cancer cells, we created tissue sections from culture cells onto membrane of culture inserts. Membranes were fixed in 10% formalin (Wako, Japan) and embedded in paraffin, using Tissue-Tek VIP and Tissue-Tek TEC Systems (Sakura Finetek, Japan). The sections were cut to 4-lm thickness and H&E) staining was carried out.
| Immunohistochemical staining
Immunostaining was undertaken using 4-lm serial tissue sections.
The sections were deparaffinized in xylene and rehydrated in a graded ethanol series. Primary antibodies used in this study are listed in Table S2 . After antigen retrieval, individual slides were incubated overnight at 4°C with primary antibody. After washing with PBS, the slides were incubated with Envision+ System HRP Labelled Polymer (Dako, CA, USA) for 30 minutes at room temperature. After washing with PBS (LSI Medience, Tokyo, Japan), the color reaction using HRP was developed for 10 minutes in 5% 3,3 0 -diaminobenzidine in imidazole-HCl buffer (pH 7.6) containing hydrogen peroxide. Finally, the sections were counterstained with Meyer's hematoxylin, dehydrated, and mounted.
| Evaluation of doxorubicin uptake by PC-9 cells
The cellular uptake quantity of anticancer drug was determined by the intracellular fluorescence intensity of doxorubicin (Kyowa Hakko, Japan). PC9-GFP cells were seeded in Col I. On day 1, medium was replaced with fresh medium with containing doxorubicin (6 lmol/L).
After 3 hours of exposure, we measured the red fluorescence intensity of GFP-positive cells. Fluorescence images were acquired using the LSM 710 confocal system mounted on a Zeiss Axio Observer Z1 microscope (Carl Zeiss, NY, USA).
| Western blot analysis
Cells were washed by PBS (Sigma-Aldrich) and were lysed in lysis buffer supplemented with phosphatase inhibitor cocktails (cOmplate Mini and PhosphoSTOP; Roche, Germany) for 30 minutes on ice.
Cell debris was removed by centrifugation at 15490 g for 30 minutes at 4°C, and the protein solution was decanted to a new tube.
The protein solution was inspissated using Amicon Ultra-4 units, with 10 kDa cut-off regenerated cellulose membranes (Millipore, MA, USA). Concentrated protein quantity was measured by Bradford assay. The protein was separated on a 7.5% or 10% SDS polyacrylamide gel and transferred to PVDF membranes (Bio-Rad, Hercules,
(#2708), and p-p70S6K (#9205) antibodies for Western blotting were all purchased from Cell Signaling Technology (Beverly, MA, USA).
| Clinical samples
All specimens were collected after obtaining written comprehensive informed consent from each patient. This study was carried out with the approval of the Institutional Review Boards of the National Cancer Center (Kashiwa, Japan) (approval no. 2014-070). All methods were carried out in accordance with the approved guidelines.
| Histopathological analysis and evaluation of the association between Col I and EGFR-TKI response
Postoperative disease-recurrent patients with lung adenocarcinoma harboring an EGFR-activating mutation were treated with gefitinib between January 2002 and December 2012. 21, 29 We selected 87 patients who were treated with gefitinib as first-line chemotherapy.
Patient characteristics are listed in Table S3 . We identified EGFR activating mutations (deletions in exon19, L858R point mutation, L861Q point mutation, or G719 missense point mutations) through either direct sequencing using Cycleave PCR (SRL Diagnostics, India), the peptide nucleic acid-locked nucleic acid (PNA-LNA) PCR-clamp method (LSI Medience), or a PCR-Invader Assay (Third Wave Technologies, WI, USA). We carried out a clinical evaluation of PFS lasting from the initiation of gefitinib treatment to the appearance of the earliest identifiable sign of disease progression, as determined by evaluation data from computed tomography or MRI imaging according to the RECIST guidelines, or until occurrence of death from any cause. We objectively quantified the positive rate of Col I by image analysis using ImageJ. In the current study, the Col I-rich stroma group was defined if >50% of the tumor area showed specifically positive reaction for Col I. 30 The distribution of patients according to
the expression level of Col I is shown in Figure S3 . The median Col I positive rate was 25.68.
| Statistical analysis
The significance of the differences between any two groups was evaluated by Student's t-test, and a difference was considered significant at P < .05. The recurrence-free survival and PFS rates were estimated using the Kaplan-Meier method, and differences in the variables were calculated by the log-rank test. A P-value <.05 was considered to indi- (n = 100) and that in the presence of Col I was 48.9 AE 4.7 lm 2 (n = 100) ( Figure S5 ). The size of PC-9 cells cultured with Col I was significantly larger than that of PC-9 cells in the absence of Col I.
This phenomenon was also observed in HCC-827 cells.
Next, we examined the phenotypic changes in PC-9 and HCC827 cells cultured with Col I. We investigated EMT-related markers, as Col I reportedly promotes EMT in cancer cells. 31 The mRNA expression of Ecadherin and vimentin was not upregulated in PC-9 cells with Col I (Figure 2A) . Immunohistochemical staining revealed the rate of E-cadherin positivity in the absence and presence of Col I was 84.9 AE 1.9%, and 84.1 AE 2.9%, respectively. Conversely, the rate for vimentin positivity 
| Drug uptake rate in PC-9 cells cultured with Col I
We considered the possibility that Col I can alter drug uptake ability.
Therefore, as gefitinib does not have autofluorescence, we used 
| Collagen type I induces mTORC1 activation in EGFR-mutant lung cancer cell lines
We hypothesized that the Col I-induced resistance in EGFR- condition (33.9 AE 1.9%) ( Figure 5C ). We investigated the combination effect of gefitinib and everolimus, another mTORC1 inhibitor for PC-9 cells, cultured with Col I. The combination treatment of gefitinib and everolimus significantly reduced the viable cell number to the same extent as without Col I ( Figure 5D ).
| Association between Col I expression within the tumor and PFS after EGFR-TKI treatment
Using human lung adenocarcinoma samples from 87 patients with postoperative recurrence who were previously treated with gefitinib, we next examined whether Col I deposition causes resistance to gefitinib treatment. We separated these patients into two groups based on Col I deposition in the total tumor area: (i) Collagen-rich group (>50% Col I-positive area, n = 6); and (ii) control group (≤50% Col I-positive area, n = 81) ( Figure 6A ). The postoperative recurrence-free survival was similar between the Collagenrich and control groups (P = .904; Figure 6B ). Conversely, the PFS of the Collagen-rich group after gefitinib treatment was significantly shorter compared to that of the control group (P = .049; Figure 6C ). by EGFR-ERK1/2-and Akt-independent signaling pathways. This is the first study to elucidate the molecular mechanism by which Col I impacts EGFR-TKI resistance. Furthermore, the current results suggest the efficacy of combination therapy of EGFR-TKI and mTOR inhibitor to relieve Col I-mediated resistance.
In this study, we found that mTOR activation plays a key role in Col I-mediated resistance. Activation of mTOR has been reported to induce anticancer drug resistance and proliferation in several cancers. [33] [34] [35] However, whether this mTOR activation by Col I is specific for EGFR activating mutation-harboring cells was unknown. We addressed this question using the EGFR WT lung adenocarcinoma cells A549, A427, and H1299. Subsequently, Col I-mediated mTOR activation was confirmed in all EGFR WT cell lines. Therefore, Col Imediated mTOR activation is a universal phenomenon ( Figure S8 ). Although it is widely known that the PI3K-Akt and MAPK signaling pathways activate mTOR, 36 our current study indicates that Col I could activate mTOR through a signaling pathway-independent mechanism. Moreover, the p-Akt antibody used in this study is specific for Serine 473. Serine 473 delivers the phosphorylation for direct mTORC2. 37 Therefore, Col I-mediated mTOR activation was not seemingly caused by mTORC2-Akt phosphorylation. There are only a few reports on mTOR activation through PI3K-Akt-and MAPK-independent signaling. 38, 39 Integrin is well known as the receptor of Col I, however, our data suggest that the integrinmediated pathway was not associated with Col I-induced mTOR activation, as FAK, a cytoplasmic tyrosine kinase that plays critical roles in integrin-mediated signaling, was not activated by Col I (Figure S5A,B) . 40, 41 There are two possible explanations to this phenomenon. One is that the receptors for Col I, other than integrin, could induce Col I-mediated mTOR activation.
Alternatively, it should be noted that mTOR functions as an amino acid sensor. It is also a conventional adjustment factor corresponding to intracellular and extracellular nutrition. 42, 43 Collagen type I is a matrix containing large quantities of amino acids. Therefore, release of amino acids from degraded Col I might cause mTOR activation. Elucidation of this molecular mechanism requires further investigation.
We evaluated the association between Col I deposition within the tumor and EGFR-TKI response in patients with postoperative recurrence harboring EGFR-activating mutations. The PFS of the Collagen-rich group after gefitinib treatment was significantly shorter compared to that of the control group, supporting current in vitro results. However, we could not measure mTOR activation in cancer cells directly by immunohistochemical analysis because of the lack of an appropriate antibody. Future consideration will be needed in order to detect this beneficial biomarker. The limitations of our analysis using patient specimens include the lower number of Collagenrich cases. Moreover, we could not exclude the possibility that Col I expression status in the primary resected tumors was also preserved, even in the recurrent tumors. The examination of the recurrent cases will be important.
In conclusion, we showed that Col I induces mTOR activation in EGFR-activating mutation-harboring cancer cells through an EGFR-ERK-1/2-and Akt-independent pathway, which results in EGFR-TKI resistance. These findings suggest that Col I acts as not only a "physiological barrier" for drug delivery but also as a "signal provider" for resistance to molecular targeted therapy. Recently, PEGPH20, which can degrade stromal hyaluronic acid, has been studied in combination with anticancer agents in pancreatic cancer. The combination of PEGPH20 and paclitaxel/gemcitabine showed a F I G U R E 6 Progression-free survival according to collagen type I (Col I) deposition in patients with lung adenocarcinoma treated with gefitinib. A, Immunohistochemical features of control (left panel) and Col I-positive (right) groups. In the control group, the proportion of Col I was 4.4%. In the Col I-rich group, the proportion of Col I was 66.5%. B, Recurrence-free survival of epidermal growth factor receptor (EGFR)-activating mutation-harboring lung adenocarcinoma patients with high Col I deposition vs control subjects. C, Progression-free survival of gefitinib-treated EGFR-activating mutation-harboring lung adenocarcinoma patients in Col I-rich vs control subjects beneficial overall response rate compared to monotherapy using paclitaxel/gemcitabine in pancreatic cancer patients highly expressing hyaluronic acid. 44 To overcome the effects of ECM composition in cancer tissue, targeting the tumor ECM could be a promising method. Our current study provides a new insight into understanding how ECM, especially Col I, regulates the drug resistance process. This study also suggests a novel strategy for increasing the therapeutic effect of EGFR-TKI.
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